SCLN Insider Trading Activity and SEC Form 4 Filings
SCLN insider trading summary
No open-market insider purchases or sales of Sciclone Pharmaceuticals Inc (SCLN) have been reported on SEC Form 4 in the past 12 months.
Latest SCLN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 16, 2017 | Lan Xie | VP Finance, China CFO | Sell | $110K (10,000 @ $11.00) |
| Aug 16, 2017 | Hong Zhao | CEO, China Operations | Sell | $330K (30,000 @ $11.00) |
| Jun 30, 2017 | Friedhelm Blobel | President & CEO | Sell | $304K (27,654 @ $11.00) |
| Jun 30, 2017 | Friedhelm Blobel | President & CEO | Sell | $81K (7,390 @ $11.00) |
| Jun 20, 2017 | Friedhelm Blobel | President & CEO | Sell | $327K (30,000 @ $10.90) |
| Jun 20, 2017 | Friedhelm Blobel | President & CEO | Sell | $437K (40,000 @ $10.91) |
| Jun 12, 2017 | Wilson Wai-Shun Cheung | CFO & Senior VP, Finance | Sell | $134K (12,500 @ $10.75) |
| Jun 12, 2017 | Wilson Wai-Shun Cheung | CFO & Senior VP, Finance | Sell | $32K (3,000 @ $10.75) |
| Jun 12, 2017 | Hong Zhao | CEO, China Operations | Sell | $32K (3,000 @ $10.75) |
| Jun 12, 2017 | Hong Zhao | CEO, China Operations | Sell | $134K (12,500 @ $10.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.